Bio Rad Laboratories (BIO) Stock Price

Bio Rad Laboratories Price

NYSE·CLOSED
356.26USD-4.93 (-1.37 %)
Market closed

Revenue has compounded at 3.8% per year over the past 19 years to 2.58 B USD. Earnings per share have grown at 11.1% per year over the last 19 years. Bio Rad Laboratories's net margin stands at 29.4%, down from 145.6% several years earlier. Analysts set a median price target of 372.30 USD, implying 4.5% above the current price. Of 10 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 47% above its 52-week low.

Bio Rad Laboratories stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Bio Rad Laboratories over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Bio Rad Laboratories stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Bio Rad Laboratories's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Bio Rad Laboratories Stock Price History
DateBio Rad Laboratories Price
8/14/2026356.26 USD
8/13/2026361.19 USD
8/12/2026362.08 USD
8/11/2026356.25 USD
8/10/2026351.34 USD
8/7/2026352.47 USD
8/6/2026342.43 USD
8/5/2026345.41 USD
8/4/2026334.39 USD
8/3/2026334.71 USD
7/31/2026325.48 USD
7/30/2026326.72 USD
7/29/2026329.40 USD
7/27/2026319.42 USD
7/23/2026316.38 USD
7/22/2026305.96 USD
7/21/2026301.70 USD
7/20/2026301.90 USD
7/17/2026304.36 USD
7/16/2026300.98 USD
7/15/2026295.73 USD
7/14/2026298.34 USD
7/13/2026298.26 USD
7/10/2026296.11 USD
7/9/2026297.28 USD
7/8/2026290.00 USD
7/7/2026292.50 USD
7/6/2026293.29 USD
7/2/2026296.86 USD
7/1/2026297.09 USD
6/30/2026293.61 USD
6/29/2026295.99 USD
6/26/2026300.79 USD
6/25/2026298.29 USD
6/24/2026280.05 USD
6/23/2026270.32 USD
6/22/2026277.88 USD
6/18/2026282.86 USD
6/17/2026289.82 USD
6/16/2026292.19 USD
6/15/2026287.62 USD
6/12/2026287.31 USD
6/11/2026290.30 USD
6/10/2026292.96 USD
6/9/2026297.17 USD
6/8/2026291.31 USD
6/5/2026297.88 USD
6/4/2026310.63 USD
6/3/2026303.79 USD
6/2/2026306.69 USD
6/1/2026309.83 USD
5/29/2026317.68 USD
5/28/2026317.98 USD
5/27/2026303.68 USD
5/26/2026290.13 USD
5/22/2026287.03 USD
5/21/2026288.46 USD
5/20/2026281.30 USD
5/19/2026281.05 USD
5/18/2026281.82 USD
5/15/2026247.53 USD
5/14/2026246.27 USD
5/13/2026243.51 USD
5/12/2026241.71 USD
5/11/2026243.79 USD
5/8/2026254.32 USD
5/7/2026257.32 USD
5/6/2026259.02 USD
5/5/2026257.12 USD
5/4/2026257.86 USD
5/1/2026256.55 USD
4/30/2026280.12 USD
4/29/2026275.15 USD
4/28/2026279.34 USD
4/27/2026287.29 USD
4/24/2026287.84 USD
4/23/2026281.42 USD
4/22/2026300.78 USD
4/21/2026305.67 USD
4/20/2026303.34 USD
4/17/2026299.02 USD
4/16/2026291.09 USD
4/15/2026295.96 USD
4/14/2026292.23 USD
4/13/2026288.17 USD
4/10/2026279.25 USD
4/9/2026277.50 USD
4/8/2026281.15 USD
4/7/2026278.00 USD
4/6/2026278.85 USD
4/2/2026279.99 USD
4/1/2026278.36 USD
3/31/2026278.75 USD
3/30/2026270.36 USD
3/27/2026265.40 USD
3/26/2026276.53 USD
3/25/2026273.60 USD
3/24/2026272.12 USD
3/23/2026265.00 USD
3/20/2026264.49 USD
3/19/2026265.00 USD
3/18/2026265.00 USD
3/17/2026269.48 USD
3/16/2026261.24 USD
3/13/2026262.80 USD
3/12/2026261.82 USD
3/11/2026269.89 USD
3/10/2026267.85 USD
3/9/2026271.44 USD
3/6/2026269.85 USD
3/5/2026279.03 USD
3/4/2026284.68 USD
3/3/2026280.19 USD
3/2/2026279.59 USD
2/27/2026278.44 USD
2/26/2026275.21 USD
2/25/2026269.65 USD
2/24/2026268.70 USD
2/23/2026268.25 USD
2/20/2026271.30 USD
2/19/2026271.90 USD
2/18/2026270.67 USD
2/17/2026264.93 USD
2/13/2026256.56 USD
2/12/2026256.56 USD
2/11/2026292.42 USD
2/10/2026293.69 USD
2/9/2026299.96 USD
2/8/2026294.90 USD
2/6/2026301.50 USD
2/5/2026301.50 USD
2/4/2026299.54 USD
2/3/2026305.90 USD
2/2/2026298.98 USD
2/1/2026297.43 USD
1/30/2026293.70 USD
1/29/2026293.70 USD
1/28/2026294.91 USD
1/27/2026299.79 USD
1/26/2026297.71 USD
1/25/2026299.28 USD
1/23/2026296.57 USD
1/22/2026296.57 USD
1/21/2026305.22 USD
1/20/2026311.54 USD
1/19/2026312.76 USD
1/16/2026313.53 USD
1/15/2026313.53 USD
1/14/2026322.06 USD
1/13/2026318.25 USD
1/12/2026322.17 USD
1/11/2026323.00 USD
1/9/2026323.82 USD
1/8/2026323.82 USD
1/7/2026319.08 USD
1/6/2026324.09 USD
1/5/2026325.50 USD
1/4/2026322.34 USD
1/2/2026305.27 USD
1/1/2026305.27 USD
12/31/2025302.99 USD
12/30/2025302.99 USD
12/29/2025304.51 USD
12/28/2025303.73 USD
12/26/2025303.88 USD
12/25/2025303.88 USD
12/24/2025301.75 USD
12/23/2025301.75 USD
12/22/2025301.03 USD
12/21/2025304.85 USD
12/19/2025301.53 USD
12/18/2025301.53 USD
12/17/2025299.86 USD
12/16/2025301.28 USD
12/15/2025302.02 USD
12/14/2025307.92 USD
12/12/2025308.13 USD
12/11/2025308.13 USD
12/10/2025313.97 USD
12/9/2025315.00 USD
12/8/2025308.05 USD
12/7/2025308.53 USD
12/5/2025317.69 USD
12/4/2025317.69 USD
12/3/2025320.06 USD
12/2/2025320.34 USD
12/1/2025318.56 USD
11/30/2025321.50 USD
11/28/2025324.86 USD
11/27/2025324.86 USD
11/26/2025327.03 USD
11/25/2025327.03 USD
11/24/2025332.21 USD
11/23/2025322.48 USD
11/21/2025316.70 USD
11/20/2025316.70 USD
11/19/2025303.61 USD
11/18/2025304.79 USD
11/17/2025307.78 USD
11/16/2025304.06 USD
11/14/2025313.15 USD
11/13/2025313.15 USD
11/12/2025316.89 USD
11/11/2025327.28 USD
11/10/2025313.33 USD
11/9/2025307.38 USD
11/7/2025305.56 USD
11/6/2025305.56 USD
11/5/2025306.55 USD
11/4/2025310.01 USD
11/3/2025310.96 USD
11/2/2025311.43 USD
10/31/2025319.55 USD
10/30/2025319.55 USD
10/29/2025304.61 USD
10/28/2025319.47 USD
10/27/2025330.42 USD
10/26/2025336.12 USD
10/24/2025339.75 USD
10/23/2025339.75 USD
10/22/2025338.67 USD
10/21/2025333.97 USD
10/20/2025331.27 USD
10/19/2025321.90 USD
10/17/2025313.02 USD
10/16/2025310.02 USD
10/15/2025312.39 USD
10/14/2025305.85 USD
10/13/2025305.05 USD
10/12/2025303.71 USD
10/10/2025297.72 USD
10/9/2025297.72 USD
10/8/2025300.63 USD
10/7/2025302.83 USD
10/6/2025296.52 USD
10/5/2025309.17 USD
10/3/2025305.54 USD
10/2/2025305.49 USD
10/1/2025294.24 USD
9/30/2025297.95 USD
9/29/2025280.39 USD
9/28/2025270.11 USD
9/25/2025271.36 USD
9/24/2025270.41 USD
9/23/2025276.62 USD
9/22/2025282.07 USD
9/21/2025283.36 USD
9/19/2025284.09 USD
9/18/2025284.07 USD
9/17/2025286.49 USD
9/16/2025280.29 USD
9/15/2025282.26 USD
9/14/2025280.21 USD
9/12/2025280.36 USD
9/11/2025280.34 USD
9/10/2025285.90 USD
9/9/2025276.91 USD
9/8/2025285.95 USD
9/7/2025290.38 USD
9/5/2025295.45 USD
9/4/2025295.43 USD
9/3/2025289.43 USD
9/2/2025288.05 USD
9/1/2025290.71 USD
8/29/2025297.90 USD
8/28/2025297.88 USD
8/27/2025293.67 USD
8/26/2025292.84 USD
8/25/2025296.60 USD
8/24/2025297.37 USD
8/22/2025307.69 USD
8/21/2025303.82 USD
8/20/2025285.03 USD
8/19/2025288.16 USD
Access this data via the Eulerpool API
Get Free API Key

Bio Rad Laboratories Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
2.67 B USD
337.80 M USD
-637.32 M USD
Jan 1, 2024
2.57 B USD
269.00 M USD
-1.84 B USD
Jan 1, 2025
2.58 B USD
270.50 M USD
759.90 M USD
Jan 1, 2026 (e)
2.57 B USD
-406.54 M USD
267.56 M USD
Jan 1, 2027 (e)
2.63 B USD
-419.88 M USD
282.93 M USD
Jan 1, 2028 (e)
2.76 B USD
-435.36 M USD
314.50 M USD
Jan 1, 2029 (e)
2.81 B USD
-442.98 M USD
343.36 M USD
Jan 1, 2030 (e)
2.89 B USD
-455.45 M USD
388.22 M USD

Bio Rad Laboratories Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 19, 2026, 4:54 AM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB USD
EBITM USD
EBIT MARGIN%
NET INCOMEB USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
2.022.072.162.292.312.552.922.802.672.572.582.572.632.762.812.89
-7.172.434.456.020.9210.1314.81-4.11-4.68-3.930.66-0.392.334.751.782.81
55.5255.0354.9553.4554.3956.4656.0655.9253.3953.7051.9951.9951.9951.9951.9951.99
1.121.141.191.221.261.441.641.571.431.381.341.341.371.431.461.50
166.0053.00115.00-108.00229.00443.00501.00482.00337.00269.00270.00-406.00-419.00-435.00-442.00-455.00
8.222.565.32-4.729.9117.4117.1517.2012.6210.4810.45-15.78-15.91-15.77-15.75-15.77
0.110.030.110.361.763.814.25-3.63-0.64-1.840.760.270.280.310.340.39
28.41-75.22307.14215.79388.33116.9511.54-185.26-82.44189.48-141.16-64.825.6211.359.2413.12
29.4729.5530.1129.8830.2230.1729.9229.7928.8228.0027.0127.0127.0127.0127.0127.01
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Bio Rad Laboratories generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Bio Rad Laboratories retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Bio Rad Laboratories's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Bio Rad Laboratories has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Bio Rad Laboratories's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Bio Rad Laboratories stock margins

The Bio Rad Laboratories margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Bio Rad Laboratories. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Bio Rad Laboratories.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
56.05 %
17.17 %
145.57 %
Jan 1, 2022
55.93 %
17.22 %
-129.45 %
Jan 1, 2023
53.42 %
12.65 %
-23.86 %
Jan 1, 2024
53.73 %
10.48 %
-71.86 %
Jan 1, 2025
52.01 %
10.47 %
29.42 %
Jan 1, 2026 (e)
52.01 %
-15.80 %
10.40 %
Jan 1, 2027 (e)
52.01 %
-15.94 %
10.74 %
Jan 1, 2028 (e)
52.01 %
-15.78 %
11.40 %

Bio Rad Laboratories Stock Revenue, EBIT, Earnings per Share

The Bio Rad Laboratories earnings per share therefore indicates how much revenue Bio Rad Laboratories has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
97.67 USD
16.77 USD
142.18 USD
Jan 1, 2022
94.06 USD
16.20 USD
-121.76 USD
Jan 1, 2023
92.70 USD
11.72 USD
-22.12 USD
Jan 1, 2024
91.67 USD
9.61 USD
-65.87 USD
Jan 1, 2025
95.63 USD
10.01 USD
28.13 USD
Jan 1, 2026 (e)
91.21 USD
-15.05 USD
9.48 USD
Jan 1, 2027 (e)
93.34 USD
-15.54 USD
10.03 USD
Jan 1, 2028 (e)
97.78 USD
-16.12 USD
11.15 USD

Bio Rad Laboratories business model & stock analysis

Bio-Rad Laboratories Inc. is a leading company in the field of scientific research based in Hercules, California. The company was founded in 1952 by two brothers and has since developed into a multinational company with over 8,000 employees worldwide. Bio-Rad has branches in over 100 countries and its products are used in biotechnology, pharmaceuticals, and the food industry. History Bio-Rad was founded in 1952 by the couple David and Alice Schwartz. They started with the production of blood group serology tests and later expanded their product range to include immunchemicals, electrophoresis equipment, and antibodies. In the 1970s, Bio-Rad developed the first commercial protein A purification system, which is still an important component of protein research today. Business model Bio-Rad's business model is focused on providing high-quality products and services to support customers in their scientific research. The company has various divisions such as life science research, clinical diagnostics, and life science education, which offer products and solutions for scientists, researchers, and diagnosticians. Life science research The life science research division offers a wide range of products and services for biological research. This includes PCR systems, electrophoresis equipment, antibodies, proteins, cell counters, and much more. Bio-Rad's products are used by scientists and researchers around the world to better understand the intricacies of life and the mechanisms of diseases. Clinical diagnostics Bio-Rad's clinical diagnostics division provides a broad spectrum of diagnostic products and solutions for hospitals, laboratories, and medical facilities. The company provides clinical diagnostic instruments, reagents, testing systems, and software to support the diagnostic process. Life science education The life science education division offers innovative and interactive teaching and learning materials for scientific research to teachers, professors, and students. Bio-Rad's products and solutions support the better understanding of the intricacies of life and the mechanisms of diseases in the fields of biology, chemistry, and physics. Products Bio-Rad offers a wide range of products and solutions for research and diagnostics. These include, among others: PCR systems: Bio-Rad offers various PCR systems that help researchers and diagnosticians amplify and analyze DNA. The systems are highly precise and provide reliable results. Proteins and antibodies: Bio-Rad offers a wide selection of proteins and antibodies for research and diagnostics. The products include various types of proteins and antibodies needed for the analysis of protein functions and interactions. Electrophoresis equipment: Bio-Rad provides various electrophoresis equipment that plays an important role in research and diagnostics. The products include gel electrophoresis systems, Western blot systems, and devices for protein analysis. Clinical diagnostics: Bio-Rad offers a wide range of diagnostic products for hospitals, laboratories, and medical facilities. These include immunoassay products, blood group serology tests, and devices for the diagnosis of infectious diseases. In summary, Bio-Rad Laboratories Inc. is a leading company in the field of scientific research. The company offers a wide range of products and solutions for research and diagnostics, supporting scientists, researchers, and diagnosticians around the world in exploring the intricacies of life and better understanding diseases.

Bio Rad Laboratories SWOT Analysis

Strengths

Bio Rad Laboratories Inc is a leading global provider of life science research and clinical diagnostics products. The company has an extensive product portfolio, ranging from instruments and reagents to software and services, catering to the needs of various scientific and healthcare professionals.

Bio Rad has a strong brand reputation and is recognized for its high-quality and innovative solutions. This reputation enables the company to attract and retain loyal customers in the highly competitive life sciences industry.

The company's research and development capabilities are a significant strength, as they allow Bio Rad to constantly introduce new products and technologies to meet changing market demands.

Weaknesses

Despite its strong market position, Bio Rad faces certain weaknesses. One of these weaknesses is its dependence on a limited number of key customers, which puts the company at risk if any of these customers reduce their purchasing volumes or switch to competitors.

Another weakness is the company's limited geographic diversification. Bio Rad operates primarily in the United States, making it vulnerable to fluctuations in the domestic market and potentially missing out on international growth opportunities.

Opportunities

Bio Rad has several opportunities for growth. The increasing global focus on healthcare and research presents opportunities for the company to expand its customer base and enhance market penetration. The growing demand for personalized medicine and genetic testing also offers new avenues for product development and revenue generation.

Furthermore, strategic partnerships and collaborations with other industry players or academic institutions can provide Bio Rad with access to complementary technologies and expertise, enabling the company to offer more comprehensive solutions to its customers.

Threats

The highly competitive nature of the life sciences industry poses a significant threat to Bio Rad. The company faces intense competition from both large multinational corporations and smaller specialized companies, which may have competitive advantages in certain niche markets.

Additionally, regulatory requirements and compliance challenges in the healthcare and life sciences sectors can pose risks and add complexity to Bio Rad's operations. Changes in regulations or failure to comply with existing ones may impact the company's ability to market and sell its products.

Bio Rad Laboratories Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Bio Rad Laboratories Employees
Details
Date
Bio Rad Laboratories Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Bio Rad Laboratories Segments

Bio Rad Laboratories Revenue by Segment (1/3)

  • 3 Years

  • 5 Years

  • Max

Clinical Diagnostics
Life Science
Details
Date
Clinical Diagnostics
Life Science
Jan 1, 2019
1.41 B USD
0.00 USD
Jan 1, 2020
1.31 B USD
1.23 B USD
Jan 1, 2021
1.52 B USD
1.40 B USD
Jan 1, 2022
1.45 B USD
1.35 B USD
Jan 1, 2023
1.49 B USD
1.18 B USD

Bio Rad Laboratories Revenue by Segment (2/3)

  • 3 Years

  • 5 Years

  • Max

All Other Segments
Details
Date
All Other Segments
Jan 1, 2019
0.00 USD
Jan 1, 2020
8.60 M USD
Jan 1, 2021
5.80 M USD
Jan 1, 2022
4.00 M USD
Jan 1, 2023
3.60 M USD

Bio Rad Laboratories Revenue by Segment (3/3)

  • 3 Years

  • 5 Years

  • Max

Life Science
All Other Segments
Details
Date
Life Science
All Other Segments
Jan 1, 2019
885.90 M USD
13.80 M USD
Jan 1, 2020
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD

Bio Rad Laboratories Revenue by Region

  • 3 Years

  • 5 Years

  • Max

United States
Europe
Asia
Other (primarily Canada and Latin America)
Details
Date
United States
Europe
Asia
Other (primarily Canada and Latin America)
Jan 1, 2019
899.10 M USD
770.30 M USD
505.00 M USD
137.30 M USD
Jan 1, 2020
1.00 B USD
857.70 M USD
546.50 M USD
136.60 M USD
Jan 1, 2021
1.13 B USD
946.90 M USD
688.40 M USD
156.60 M USD
Jan 1, 2022
1.16 B USD
851.90 M USD
639.40 M USD
155.40 M USD
Jan 1, 2023
1.12 B USD
819.80 M USD
563.00 M USD
166.60 M USD
Jan 1, 2024
1.04 B USD
834.10 M USD
521.60 M USD
169.30 M USD
Jan 1, 2025
1.02 B USD
881.80 M USD
513.30 M USD
165.40 M USD

Bio Rad Laboratories Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Bio Rad Laboratories historical P/E ratio, EBIT multiple, and P/S ratio

Bio Rad Laboratories annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Bio Rad Laboratories shares outstanding

The number of shares of Bio Rad Laboratories was 27.01 M in 2025. This indicates how many shares Bio Rad Laboratories is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
29.92 M Stocks
Jan 1, 2022
29.79 M Stocks
Jan 1, 2023
28.82 M Stocks
Jan 1, 2024
28.00 M Stocks
Jan 1, 2025
27.01 M Stocks
Jan 1, 2026 (e)
27.01 M Stocks
Jan 1, 2027 (e)
27.01 M Stocks
Jan 1, 2028 (e)
27.01 M Stocks

Current Bio Rad Laboratories forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
60.00 % (6)
Hold
40.00 % (4)
Sell
0.00 % (0)
12M Price Target
372.30
Last Price
356.26
Currency
USD
12M Return Potential
4.50 %
LTM Return
0 %

Bio Rad Laboratories Analyst Rating Actions

DateFirmActionRatingReliability
5/1/2026
Wells Fargo
Wells Fargo
MaintainedEqual Weight56
4/7/2026
Citigroup
Citigroup
DowngradeBuyNeutral48
2/16/2026
Wells Fargo
Wells Fargo
MaintainedEqual Weight56
10/30/2025
Wells Fargo
Wells Fargo
MaintainedEqual Weight56
10/30/2025
Citigroup
Citigroup
MaintainedBuy48
8/1/2025
Wells Fargo
Wells Fargo
MaintainedEqual Weight56
8/1/2025
RBC Capital
RBC Capital
MaintainedOutperform52
6/9/2025
Wells Fargo
Wells Fargo
MaintainedEqual Weight56
5/2/2025
UBS
UBS
MaintainedBuy51
5/2/2025
RBC Capital
RBC Capital
MaintainedOutperform52

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Bio Rad Laboratories Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
7/30/20261.77USD-630.23 MUSD-2026 Q2
4/30/20262.00USD-594.76 MUSD-2026 Q1
2/12/20262.74USD-700.89 MUSD-2025 Q4
5/2/20243.35USD-673.76 MUSD-2024 Q1
2/14/20242.89USD-692.41 MUSD-2023 Q4
7/28/20222.83USD-692.86 MUSD-2022 Q2
8/7/20181.28USD-556.66 MUSD-2018 Q2

EESG©

Eulerpool ESG Scorecard© for the Bio Rad Laboratories stock

41/100
41
Environment
62
Social
20
Governance
E

Environment

20
Scope 1 - Direct Emissions10,563
Scope 2 - Indirect emissions from purchased energy13,906
Scope 3 - Indirect emissions within the value chain295,930
Total CO₂ emissions24,469
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees44
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Bio Rad Laboratories shareholder structure

% Name
9.22511%
FIRST EAGLE INVESTMENT MANAGEMENT, LLC
FIRST EAGLE INVESTMENT MANAGEMENT, LLC
5.95470%
BLACKROCK, INC.
BLACKROCK, INC.
3.86093%
DIMENSIONAL FUND ADVISORS LP
DIMENSIONAL FUND ADVISORS LP
2.94593%
VANGUARD CAPITAL MANAGEMENT LLC
VANGUARD CAPITAL MANAGEMENT LLC
2.93892%
VANGUARD PORTFOLIO MANAGEMENT LLC
VANGUARD PORTFOLIO MANAGEMENT LLC
2.78571%
ARIEL INVESTMENTS, LLC
ARIEL INVESTMENTS, LLC
...

Bio Rad Laboratories Beneficial Ownership Filings (SEC 13D/G)

Free Float
66.1%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
87.40%
Schwartz
Schwartz
SEC ↗
83.70%
943334150
943334150
SEC ↗
80.80%
Steven D. Schwartz
Steven D. Schwartz
SEC ↗
80.10%
Blue Raven Partners, L.P.
Blue Raven Partners, L.P.
SEC ↗
79.20%
Blue Raven Partners, L.P., 943334150
Blue Raven Partners, L.P., 943334150
SEC ↗
14.60%
Norman D. Schwartz
Norman D. Schwartz
SEC ↗
12.30%
Alice N. Schwartz
Alice N. Schwartz
SEC ↗
11.40%
First Eagle Investment Management, LLC
First Eagle Investment Management, LLC
SEC ↗
11.00%
Eaton Vance Management 04-3101341
Eaton Vance Management 04-3101341
SEC ↗
9.70%
BIO-RAD LABORATORIES, INC
BIO-RAD LABORATORIES, INC
SEC ↗

Bio Rad Laboratories Executives and Management Board

16 members · avg. age 60 · 31 % women

NS

Mr. Norman Schwartz (75)

Chairman of the Board, Chief Executive Officer · since 1995

8.29 M USD

Management

JD

Mr. Jonathan Divincenzo (59)

President, Chief Operating Officer

4.31 M USD
RL

Mr. Roop Lakkaraju (54)

Chief Financial Officer, Executive Vice President

3.78 M USD
MC

Mr. Michael Crowley (63)

Executive Vice President - Global Commercial Operations

2.24 M USD
EE

Ms. Eva Anette Engelhardt (55)

Executive Vice President, President of Clinical Diagnostics Group

2.23 M USD
CE

Ms. Courtney Enloe (53)

Executive Vice President, General Counsel, Secretary

–
CC

Ms. Colleen Corey (63)

Executive Vice President, Global Human Resources

–

Board of Directors

GH

Mr. Gregory Hinckley (78)

Lead Independent Director

339,563.00 USD
ML

Ms. Melinda Litherland (67)

Independent Director

331,563.00 USD
JE

Mr. Jeffrey Edwards (64)

Independent Director

326,563.00 USD
AP

Mr. Arnold Pinkston (66)

Independent Director

311,563.00 USD
AS

Ms. Allison Schwartz (44)

Director

–

Bio Rad Laboratories Supply Chain

Bio Rad Laboratories Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
14 companies
#Nameβ 1YTrend
1
Sartorius Vz
Supplier·Customer·DE
0.39
0.51
0.86
0.96
0.96
0.94
—
2
Danaher Corporation
Customer·Life Sciences Tools & Services·US
0.89
0.85
0.92
0.92
0.90
0.87
0.89
3
Biotest Vz I
Supplier·DE
-0.17
0.14
-0.26
0.83
0.40
0.68
—
#Nameβ 1YTrend
1
Quantum-Si A
Supplier·Customer·Life Sciences Tools & Services·US
0.97
0.58
0.61
0.84
0.64
—
—
2
Seegene, Inc.
Customer·Biotechnology·KR
0.78
0.54
0.58
0.82
0.54
—
0.92
3
Luminex Corporation
Supplier·US
0.58
0.46
-0.25
-0.89
-0.90
—
-4.05
4
DCC plc
Customer
-0.09
-0.43
—
—
—
—
—
5
Biodesix
Supplier·Customer·Health Care Providers & Services·US
-0.47
-0.25
0.36
0.85
0.59
—
—

Frequently asked questions about Bio Rad Laboratories

The business model of Bio Rad Laboratories Inc. revolves around refining and providing innovative solutions for the life science research and diagnostic markets. As a leading global provider of products and systems, Bio Rad Laboratories Inc. focuses on developing and manufacturing a wide range of specialized products. These include instruments, reagents, consumables, software, and services that cater to medical diagnostics, scientific research, and biopharmaceutical production. By continuously investing in research and development, Bio Rad Laboratories Inc. aims to meet the diverse needs of its customers, drive scientific advancements, and improve patient outcomes worldwide.

Bio Rad Laboratories Inc operates primarily in the Life Sciences and Clinical Diagnostics industries. As a leading global provider of specialty diagnostic solutions, Bio Rad offers a wide range of products and services for scientific research and healthcare diagnostics. The company specializes in developing and manufacturing instruments, reagents, software, and consumables for applications in life science research, clinical laboratories, and pharmaceutical production. With a focus on advancing scientific discovery and improving patient healthcare, Bio Rad Laboratories Inc plays a crucial role in the fields of molecular biology, genomics, proteomics, and more.

Some of the main competitors of Bio Rad Laboratories Inc in the market include Thermo Fisher Scientific Inc, PerkinElmer Inc, and Illumina Inc.

Bio Rad Laboratories Inc, established in 1952, is a global leader in life science research and clinical diagnostics. The company's rich history spans over several decades, during which it has consistently provided innovative solutions to scientists and healthcare professionals. Bio Rad initially focused on the development of specialized products for the growing field of biochemical research, and later expanded into medical diagnostics and life science technologies. Today, Bio Rad continues to deliver cutting-edge technology, spanning areas such as genomics, proteomics, cell biology, food safety, and more. With a commitment to excellence and advancements in healthcare, Bio Rad Laboratories Inc remains a trusted name in the scientific community.

Bio Rad Laboratories Inc has accomplished several significant milestones. From its inception in 1952, the company has become a global leader in life science research and clinical diagnostics. One noteworthy achievement is the development of ground-breaking products, such as the first digital imaging system for electrophoresis analysis, which revolutionized the field. Bio Rad also played a crucial role in advancing HIV/AIDS diagnostics and monitoring through the introduction of reliable testing systems. Additionally, the company's continuous dedication to innovation has led to expansions in various areas, including food safety and quality control, further strengthening its position as a trusted provider of scientific solutions across industries. Bio Rad Laboratories Inc remains committed to driving advancements and enhancing scientific research globally.

Bio Rad Laboratories Inc is primarily present in the United States, with its headquarters located in Hercules, California. Aside from its domestic presence, Bio Rad operates internationally in various countries and regions. This includes Europe (with offices in the United Kingdom, France, Germany, and other countries), Asia-Pacific (including Japan, China, Korea, and Australia), Latin America, and Canada. With its extensive global footprint, Bio Rad Laboratories Inc continues to expand its reach and serve customers worldwide in the life sciences and clinical diagnostics industries.

Bio Rad Laboratories Inc represents a strong set of values and a dedicated corporate philosophy. The company is committed to providing innovative solutions and high-quality products in the life sciences and clinical diagnostics fields. Bio Rad prioritizes excellence, integrity, and teamwork in all its endeavors. With a focus on customer satisfaction, Bio Rad strives to deliver superior value and support to its clients. The company's relentless dedication to scientific advancement and commitment to ethical and responsible business practices contribute to its reputable standing in the industry.

Analysts currently set an average price target of 362.10 USD for the Bio Rad Laboratories stock (median: 372.30 USD), implying +1.6 % versus the latest price. The consensus is based on 10 analyst ratings.

Bio Rad Laboratories Analyst Price Targets 2026

10 analysts currently rate the Bio Rad Laboratories stock: 6 recommend buying, 4 holding and 0 selling. For 2026, analysts expect Bio Rad Laboratories to generate revenue of 2.57 B USD and earnings per share of 9.91 USD.

Bio Rad Laboratories Analyst Price Targets 2026

Converted at the current exchange rate, the Bio Rad Laboratories share trades at 307.76 EUR (356.26 USD).

The Bio Rad Laboratories share (BIO) is listed on 6 stock exchanges, including: NYSE (BIO), XETRA (BUWA.DE), Frankfurt (BUWA.F), München (BUWA.MU), Düsseldorf (BUWA.DU), SIX (Zürich) (BUWA.SW).

Bio Rad Laboratories Inc is a globally operating company in the field of life science research, diagnostics, and biopharmaceuticals. The company offers a wide range of innovative products and services for research institutions, biotechnology and pharmaceutical companies, as well as customers in clinical diagnostics. The business strategy of Bio Rad Laboratories is based on three pillars: product innovation, diversification, and global expansion. The company continuously invests in research and development to develop new products and services that meet the needs of its customers. Thanks to the diversification of its product lines, Bio Rad Laboratories is able to expand in various areas of life sciences and address a wide spectrum of customers. The company is divided into six main business areas: 1. Life Science Research Bio Rad Laboratories offers a comprehensive range of life science research products for research in genomics, proteomics, cell biology, and immunology. Products include DNA isolation kits, PCR reagents, protein separation systems, and antibody solutions. 2. Diagnostics Bio Rad Laboratories is a leading provider of in vitro diagnostics and QC/QA products. The company offers diagnostic products for clinical chemistry, hematology, immunology, and microbiology. 3. Biopharma Bio Rad Laboratories offers a wide range of solutions for biopharmaceuticals, including chromatography columns, protein purification systems, and analysis equipment. 4. Food Science Bio Rad Laboratories offers products for food quality assurance. This includes products for the identification of contaminants in food, such as salmonella, E. coli, and other bacterial contaminations, as well as for testing the nutrient quality in food. 5. Process Separations Bio Rad Laboratories offers a comprehensive range of chromatography columns and accessories used for downstream purification of proteins and other biomolecules in biopharmaceuticals and the food industry. 6. Digital Biology Bio Rad Laboratories offers solutions for digital PCR analysis with its droplet digital PCR technology. This technology allows for the quantification of nucleic acids on an absolute basis and can be used in numerous applications in research and diagnostics. The company also offers software solutions that simplify and standardize data recording and analysis in laboratory tests. The offered software solutions include laboratory information management systems (LIMS), chromatography software, and data analysis tools. Bio Rad Laboratories' customers include research institutions, biotechnology and pharmaceutical companies, as well as customers in clinical diagnostics. The company's products and services are sold in over 100 countries worldwide. In conclusion, Bio Rad Laboratories offers a wide portfolio of products and services in the field of life science research, diagnostics, and biopharmaceuticals. The company pursues a business strategy based on product innovation, diversification, and global expansion. Thanks to the wide range of products and services designed for different business areas, Bio Rad Laboratories is able to serve a broad spectrum of customers worldwide.

The expected revenue of Bio Rad Laboratories is 2.57 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Bio Rad Laboratories is 267.56 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Bio Rad Laboratories is currently 35.97. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Bio Rad Laboratories stock.

The price-to-sales ratio (P/S) of Bio Rad Laboratories is currently 3.74. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Bio Rad Laboratories stock.

The Eulerpool Quality Score for Bio Rad Laboratories is 2/10.

The ISIN of Bio Rad Laboratories is US0905722072. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Bio Rad Laboratories is 865406. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Bio Rad Laboratories is BIO. The ticker symbol is used to trade Bio Rad Laboratories shares on the stock exchange.

Bio Rad Laboratories paid dividends every year for the past 0 years.

Bio Rad Laboratories is assigned to the 'Health' sector.

The dividends of Bio Rad Laboratories are distributed in USD.

All fundamentals and in-depth analysis of Bio Rad Laboratories

Our stock analysis for Bio Rad Laboratories stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bio Rad Laboratories. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Bio Rad Laboratories Stock
Bio Rad Laboratories Revenue→
Bio Rad Laboratories Stock
Bio Rad Laboratories Net Income→
Bio Rad Laboratories Stock
Bio Rad Laboratories P/E→
Bio Rad Laboratories Stock
Bio Rad Laboratories P/S→
Bio Rad Laboratories Stock
Bio Rad Laboratories EBIT→
Bio Rad Laboratories Stock
Bio Rad Laboratories Dividend→
Bio Rad Laboratories Stock
Bio Rad Laboratories Directors Dealings→
Bio Rad Laboratories Stock
Bio Rad Laboratories Stocks→
Bio Rad Laboratories Stock
Bio Rad Laboratories Market capitalization→
Bio Rad Laboratories Stock
Bio Rad Laboratories Debt→
Bio Rad Laboratories Stock
Bio Rad Laboratories Liabilities→
Bio Rad Laboratories Stock
Bio Rad Laboratories Equity→
Bio Rad Laboratories Stock
Bio Rad Laboratories AAQS→
Bio Rad Laboratories Stock
Bio Rad Laboratories Employees→
Bio Rad Laboratories Stock
Bio Rad Laboratories ROE→
Bio Rad Laboratories Stock
Bio Rad Laboratories ROA→
Bio Rad Laboratories Stock
Bio Rad Laboratories ROCE→
Bio Rad Laboratories Stock
Bio Rad Laboratories News→
Bio Rad Laboratories Stock
Bio Rad Laboratories Analyst Price Targets→

Health Stocks

Bio Solution CoBio Preventive MedicineBio ViewBio Plus CoBio-FD&C CoBio Path HoldingsBio-TechneBio Green Med SolutionBio-Thera SolutionsBinex CoBio-Works TechnologiesBimergen EnergyAll Stocks A–Z →